The research, conducted at Kagoshima University in Japan, followed 185 adults with newly diagnosed glioblastoma treated between 2011 and 2020. Rather than assessing walking at a single moment, the investigators tracked it at six distinct points spanning the treatment trajectory: before surgery, on postoperative day five, before the start of chemoradiotherapy, at hospital discharge, and at one and four months after discharge. The instrument they chose was the Functional Ambulation Category, or FAC, a six-point ordinal scale that classifies walking according to the level of human assistance required, ranging from nonfunctional ambulation at level 0 to fully independent walking on all surfaces at level 5. Because the scale depends on observation of assistance rather than timed performance, it remains feasible even in patients whose motor impairment, reduced consciousness, aphasia, or cognitive dysfunction would make stopwatch-based gait tests impractical or impossible.

The study’s central finding is striking in its consistency. Higher FAC scores were associated with longer overall survival at all six assessment points, but the association was strongest at hospital discharge. When patients were grouped by discharge walking ability, median survival measured from surgery was 346 days for those with FAC 0 to 1, 590 days for those with FAC 2 to 4, and 879 days for those with FAC 5, a gradient that the log-rank test confirmed was highly unlikely to arise by chance. Using hospital discharge as a landmark origin for survival measurement, median post-discharge survival was 286, 531, and 823 days for the three groups respectively, again with a highly significant overall difference. Patients unable to walk or requiring constant human support separated clearly from those with partial independence, while the distinction between partial assistance and full independence narrowed once statistical corrections for multiple comparisons were applied.

The methodological care behind these numbers deserves attention. In the primary analysis, the researchers used a discharge-landmark design in 162 patients with 138 deaths, aligning the survival clock with the assessment itself and adjusting hazard estimates for age, sex, extent of resection, and the Karnofsky Performance Status measured at the same discharge moment. Against the reference group with FAC 0 to 1, the adjusted hazard ratio for death was 0.45 for patients with FAC 2 to 4 and 0.33 for those who walked fully independently, meaning that better walking categories were associated with mortality risks roughly half to a third of those seen in the most impaired group. Discharge Karnofsky Performance Status itself remained independently prognostic, with each ten-point increase associated with a fourteen percent lower hazard of death, which makes the persistence of the FAC signal all the more notable.

To determine whether the walking measure truly added information beyond global performance status, the team compared statistical models with and without discharge FAC using the Akaike information criterion, Harrell’s concordance index, and a likelihood-ratio test. Adding FAC improved model fit by 8.4 AIC units and improved discrimination by 0.022 on the C-index, a modest but statistically significant gain with a p value of 0.002. In a head-to-head comparison of the four in-hospital assessments on a common complete-case subset, discharge FAC produced the largest improvement over the clinical reference model, with an AIC gain of 20.1 and a C-index improvement of 0.043, while earlier assessments contributed less. Systematic landmark sensitivity analyses that shifted the survival origin to match each assessment reproduced the same temporal pattern, reinforcing that the discharge measurement sits at a uniquely informative moment in the clinical course.

The authors are careful to explain why discharge, rather than any earlier or later point, carries the strongest signal. Discharge FAC is measured only after surgery, early postoperative recovery, inpatient rehabilitation, and a substantial portion of the initial chemoradiotherapy course have already unfolded. It therefore functions as an integrated clinical marker, summarizing the net effect of tumor biology, treatment intensity, surgical sequelae, and functional recovery up to a meaningful transition point, rather than as a purely baseline prognostic factor. Walking ability in the cohort followed a characteristic trajectory: lowest immediately after surgery, then progressively recovering toward discharge and beyond. This pattern carries a practical clinical warning, namely that early postoperative deterioration should not automatically be read as a patient’s eventual functional ceiling, since meaningful recovery often continues throughout hospitalization.

The findings also illuminate the relationship between function and treatment delivery. Patients with higher discharge FAC were markedly more likely to begin post-discharge adjuvant temozolomide, with initiation rates of 60 percent in the FAC 0 to 1 group, 90 percent in the FAC 2 to 4 group, and 98 percent in the FAC 5 group. This suggests that walking ability may partly serve as a proxy for treatment readiness, the physiological and cognitive reserve required to tolerate continued intensive therapy. Importantly, statistical adjustment for adjuvant temozolomide did not materially change the FAC estimates, and the authors emphasize that because exact initiation dates were unavailable, the findings establish prognostic association rather than a causal effect of walking recovery or rehabilitation on survival. Subgroup analyses found the inverse association present in every stratum of age, sex, preoperative performance status, and extent of resection, with no significant interactions; the age interaction p value of 0.783 argues against the possibility that the effect simply reflects younger patients walking better.

The study Situates itself against a backdrop of mixed prior evidence. Earlier work had associated balance performance with subsequent loss of walking ability and mortality in glioblastoma, while timed tests such as the ten-meter walk test and the six-minute walk test failed to emerge as independent survival predictors in their respective cohorts. This new study extends the evidence to an assistance-based, non-timed measure, one that can be assigned at the bedside without equipment or patient cooperation with standardized testing. Reliability support came from a substudy of 71 patients in whom a second physical therapist independently assigned discharge FAC ratings, yielding a linear weighted Cohen’s kappa of 0.819, indicating strong agreement for chart-based assessment. Rehabilitation was delivered within an integrated institutional pathway that initiated inpatient rehabilitation typically within three days of surgery and continued it throughout chemoradiotherapy, a context that shaped both the long median hospital stay of 63 days and the timing of the discharge assessment itself.

The investigators are forthright about the limitations that temper interpretation. The retrospective, single-center design, the absence of systematically collected IDH and MGMT molecular data across the historical cohort, possible misclassification under contemporary WHO diagnostic criteria, heterogeneous treatment including upfront bevacizumab, and the inability to model corticosteroid exposure all leave room for residual confounding. The three-group FAC categorization requires external validation, and the incremental gain in discrimination, while real, was modest. The authors accordingly position discharge FAC not as a stand-alone prediction tool or a validated clinical model, but as a practical, complementary bedside marker available precisely at the transition from inpatient treatment to post-discharge care, before further survivor selection accumulates. Within that frame, the message is clear and clinically actionable: in newly diagnosed glioblastoma, how a patient walks on the day they leave the hospital encodes prognostic information that global performance scores alone do not fully convey, and it can be captured with nothing more than an attentive clinical eye. Future multicenter prospective studies, the authors conclude, should validate the finding and explore how walking independence integrates with neurological, oncological, and supportive-care factors in modern, molecularly stratified glioblastoma care.

Subject of Research: Prognostic value of walking ability at hospital discharge for overall survival in newly diagnosed glioblastoma

Article Title: Prognostic significance of walking ability at hospital discharge for overall survival in newly diagnosed glioblastoma: a comparison across six peri-treatment assessments

Article References: Prognostic significance of walking ability at hospital discharge for overall survival in newly diagnosed glioblastoma: a comparison across six peri-treatment assessments. (n.d.). https://doi.org/10.1007/s11060-026-05784-0

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05784-0

Keywords: glioblastoma, walking ability, Functional Ambulation Category, hospital discharge, overall survival, prognosis, Karnofsky Performance Status, rehabilitation, chemoradiotherapy, brain tumor, functional outcomes, neuro-oncology

In research published on October 11, 2025, in the journal Neuro-Oncology, an interdisciplinary team led by Associate Professor Akifumi Hagiwara at Juntendo University uncovered profound disruptions in the contralateral hemisphere’s neurofluid dynamics in IDH wild-type glioblastoma patients. The contralateral hemisphere is the area of the brain opposite to the tumor and traditionally regarded as relatively unaffected. By employing cutting-edge magnetic resonance imaging (MRI) modalities, the study demonstrated that abnormal fluid circulation patterns far from the tumor could independently predict patient survival outcomes—regardless of tumor size, location, or genetic markers.

The brain’s internal fluid circulation system, known as the glymphatic system, acts as a sophisticated clearance mechanism that facilitates the removal of metabolic waste, proteins, and cellular debris. This channel follows along vascular pathways and perivascular spaces, maintaining cerebral homeostasis. The study’s findings challenge the prevailing perception of glioblastoma as a strictly localized disease, revealing that pathological processes compromise brain-wide fluid dynamics. “We observed that even structures distant from the tumor site exhibited significant impairment in fluid flow,” explained Dr. Hagiwara. “This disruption correlated strongly with reduced survival rates, underscoring glioblastoma’s systemic impact on the brain’s microenvironment.”

To investigate neurofluid dynamics with precision, the researchers utilized two specialized MRI markers: Diffusion Tensor Imaging analysis along the Perivascular Space (DTI-ALPS) and Free Water (FW) imaging. DTI-ALPS provides a sensitive measure of water molecule movement along perivascular channels—the microscopic conduits responsible for glymphatic flux—while FW imaging quantifies the accumulation of extracellular free water within brain tissue. Decreased ALPS indices indicate sluggish water transport, whereas elevated free water content suggests fluid stagnation and edema. Both metrics, when abnormal in the contralateral hemisphere, emerged as robust indicators of poor patient prognosis.

Extensive analysis of MRI datasets from 546 patients across multiple clinical cohorts revealed a compelling association: patients exhibiting preserved glymphatic function with higher ALPS indices and lower free water levels had markedly longer survival times compared to those with disrupted neurofluid flow. Remarkably, these alterations occur in the hemisphere opposite the neoplasm, suggesting a pervasive disruption of cerebral fluid mechanics rather than a purely tumor-centric phenomenon. This insight compels a paradigm shift, advocating for the evaluation of neurofluid status beyond the immediately visible tumor margins.

The clinical implications of these findings are numerous and profound. The ability to noninvasively quantify neurofluid dynamics via advanced MRI may soon become integral to personalized therapeutic strategies. Patients demonstrating compromised glymphatic integrity might benefit from intensified treatment regimens, potentially including novel immunotherapies or pharmacologic agents designed to restore homeostatic fluid balance within the brain. This approach could complement conventional interventions, enabling clinicians to stratify patients more effectively according to their individual pathophysiology.

Moreover, Dr. Hagiwara envisions a future where these imaging biomarkers facilitate early identification of glioblastoma patients at heightened risk of rapid disease progression. Tailoring treatments to improve neurofluid circulation could not only extend survival but also enhance quality of life by mitigating secondary cerebral damage caused by toxic waste accumulation. Beyond oncology, this research opens promising avenues for understanding other neurological disorders where glymphatic dysfunction plays a central role, such as Alzheimer’s disease and various dementias.

Therapeutic innovation may soon extend to modulation of the glymphatic system itself. Emerging approaches include optimizing sleep patterns—known to enhance glymphatic clearance—targeting neuroinflammation, and manipulating the function of aquaporin water channels integral to cerebral fluid transport. By bolstering the brain’s natural “plumbing” mechanisms, future adjunctive therapies might mitigate the microenvironmental damage that accelerates tumor progression and neurodegeneration alike.

This study fundamentally reframes glioblastoma as a disorder involving both cellular proliferation and a compromised neurofluid environment. Understanding the pathophysiological interplay between tumor biology and the brain’s clearance systems may unlock transformative treatment modalities. “Glioblastoma is not simply uncontrolled cellular growth,” emphasized Dr. Hagiwara, “it also involves a failure of the brain to maintain its internal environment, critically influencing patient outcomes.”

Advanced MRI analyses like DTI-ALPS and FW imaging provide unprecedented windows into the brain’s hidden fluid dynamics. These capabilities allow clinicians to transcend traditional anatomical imaging limitations, capturing the functional state of vital clearance pathways. As this research gains validation through further clinical studies, incorporating neurofluid imaging into routine glioblastoma assessments could become standard practice, dramatically refining prognostic accuracy and therapeutic decision-making.

The study’s interdisciplinary collaboration among radiologists, data scientists, and neurosurgeons at Juntendo University exemplifies the power of integrative research in tackling complex brain disorders. Insights from this work may ripple across neuroscience fields, inspiring novel biomarker development and therapeutic frameworks targeting brain-wide homeostasis. Ultimately, leveraging these neurofluid signals offers hope for improving survival rates in a disease long marked by grim prognoses.

By uncovering the contralateral hemisphere’s role in glioblastoma progression, this research uncovers an essential but previously underappreciated layer of disease biology. Restoring balance within the brain’s glymphatic system promises not only to transform glioblastoma management but also to catalyze advances across neuro-oncology and neurodegenerative disease landscapes. As the scientific community embraces this new perspective, renewed optimism emerges for patients confronting the formidable challenges of brain cancer.

Subject of Research: People

Article Title: Contralateral Neurofluid Dynamics Predict Survival in IDH Wild-Type Glioblastoma: A DTI-ALPS and Free Water Imaging Study

News Publication Date: October 11, 2025

Web References:
https://doi.org/10.1093/neuonc/noaf242

References:
Hagiwara A, Uchida W, Ozawa T, et al. Contralateral Neurofluid Dynamics Predict Survival in IDH Wild-Type Glioblastoma: A DTI-ALPS and Free Water Imaging Study. Neuro-Oncology. 2025. https://doi.org/10.1093/neuonc/noaf242

Image Credits:
Professor Akifumi Hagiwara, Faculty of Medicine, Juntendo University, Japan

Keywords: Brain tumors, Magnetic resonance imaging, Glymphatic system, Neurofluid dynamics, Glioblastoma, DTI-ALPS, Free Water Imaging

Glioblastoma remains among the deadliest brain tumors, with survival times varying widely among patients, complicating therapeutic decision-making. Despite improvements in therapy, precision in predicting patient prognosis has lagged behind, largely due to the heterogeneous nature of the tumor. The 2021 World Health Organization classification recognizes this heterogeneity, particularly highlighting the IDH-wt subtype, which lacks targeted molecular therapies and exhibits variable progression rates.

The research team retrospectively studied a cohort of 369 IDH-wt GBM patients. This sizable dataset included 273 patients from three hospitals, divided into training and testing groups, and 96 patients from The Cancer Imaging Archive (TCIA) serving as an independent validation set. Such comprehensive data pooling is rare and critical for developing robust models that generalize well across different clinical populations and imaging protocols.

Central to their methodology was the extraction of radiomics features from both the tumor core and the surrounding peritumoral edema visible on preoperative contrast-enhanced T1-weighted MRI (CE-T1WI) and T2-weighted fluid-attenuated inversion recovery (T2 FLAIR) sequences. Radiomics involves the transformation of medical images into high-dimensional data, capturing subtle textural and spatial patterns that are inaccessible to the naked eye but potentially reflect underlying pathophysiology.

Through rigorous statistical analyses including univariate screening and least absolute shrinkage and selection operator (LASSO) Cox regression, the investigators distilled numerous radiomics features into a refined radiomics-based prognostic model. This model was capable of categorizing patients into distinct high-risk and low-risk groups according to their predicted survival, demonstrating strikingly higher performance metrics than traditional clinical models that rely on well-known risk factors alone.

The clinical risk model, based on conventional clinical variables and patient demographics, showed moderate predictive ability; however, the radiomics model consistently outperformed it across training, testing, and validation cohorts, with concordance indexes (C-index) ranging from 0.69 to 0.76. The combined model, which integrated both radiomics and clinical features using an advanced machine learning technique known as Random Survival Forests, yielded the best predictive accuracy, pushing C-index values up to nearly 0.79 in the training set.

Remarkably, this combined model represented an approximate 12.57% improvement in survival stratification capability over the clinical model, underscoring the additive value of incorporating quantitative imaging biomarkers. This improvement holds the potential to significantly impact clinical decision-making, allowing clinicians to better tailor treatment regimens based on individualized risk profiles.

Beyond mere prognostication, the study also ventured into the biological underpinnings of the radiomics findings. By examining differential gene expression between molecularly defined high-risk and low-risk groups identified by the combined model, the researchers uncovered compelling evidence linking the activation of Gamma-aminobutyric acid (GABA) receptor-related pathways with aggressive tumor behavior and poorer outcomes.

GABA, best known as a central nervous system inhibitory neurotransmitter, has increasingly been recognized for its role in cancer biology, influencing tumor cell proliferation, migration, and interaction with the tumor microenvironment. The activation of GABA receptor pathways in high-risk glioblastomas could open new avenues for therapeutic targeting, shifting the paradigm toward receptor modulation alongside traditional oncologic therapies.

This intersection of imaging phenotypes with underlying molecular biology enhances our understanding of glioblastoma heterogeneity and reinforces the potential for radiogenomics—a fusion of radiomics and genomics—to revolutionize personalized oncology. The approach circumvents the need for invasive tissue sampling while generating actionable insights driving precision medicine.

Importantly, the study’s design utilizing multiple independent datasets strengthens confidence in the generalizability of their findings. The use of standardized MRI sequences and thorough validation minimizes biases commonly seen in retrospective imaging biomarker research, hence supporting potential future clinical implementation.

While the study focused on newly classified WHO 2021 criteria IDH-wt GBM, its methodologies could be readily extended to other molecularly distinct brain tumor subtypes and even beyond neuro-oncology. Leveraging radiomics for survival prediction may ultimately transform how clinicians assess tumor aggressiveness, monitor disease progression, and optimize patient-specific therapeutic choices.

As artificial intelligence and machine learning techniques continue to evolve and integrate with clinical workflows, this convergence exemplified by the combined radiomics-biological model marks a crucial step toward truly individualized cancer care. It opens exciting prospects for real-time, noninvasive tumor characterization that can adapt dynamically as tumor biology changes.

Nevertheless, translating these findings into routine clinical practice will require further prospective studies and real-world validation to assess utility, cost-effectiveness, and workflow integration. Prospective clinical trials assessing treatment response predicated on radiomics risk stratification could solidify clinical adoption.

To summarize, this landmark research not only introduces a novel survival risk stratification tool rooted in cutting-edge MRI radiomics and biological exploration but also highlights key molecular pathways amenable to future therapeutic innovation. It sets a new standard for prognostic modeling in IDH-wt glioblastoma and exemplifies the promise of precision neuro-oncology in the era of data-driven medicine.

Subject of Research: Survival risk stratification in 2021 WHO isocitrate dehydrogenase wild type glioblastoma using MRI radiomics and biological pathway analysis.

Article Title: Survival risk stratification of 2021 WHO glioblastoma by MRI radiomics and biological exploration.

Article References:
Li, Y., Xu, W., Zhao, C. et al. Survival risk stratification of 2021 WHO glioblastoma by MRI radiomics and biological exploration. BMC Cancer 25, 1505 (2025). https://doi.org/10.1186/s12885-025-14906-2

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14906-2